Intellia Therapeutics Head office building

Press Releases

Intellia Therapeutics, Novartis Form Collaboration to Develop New Cell Therapies Using CRISPR/Cas9 Technology

Five-Year Collaboration Focused on CART and Hematopoetic Stem Cell Applications across a Range of Therapeutic Areas CAMBRIDGE, Mass.—January 7, 2015—Intellia Therapeutics, a leader in the development of therapeutic products using CRISPR/Cas9 technology for gene editing and repair, today announced a
Read More

Intellia Therapeutics Announces $15 Million in Funding to Develop Therapeutic Products Utilizing CRISPR-Cas9 Gene Editing Technology

Scientific Pioneers, Industry Veterans Advance Company toward IND Filing CAMBRIDGE, Mass.—November 18, 2014—Intellia Therapeutics, a new company formed to develop therapeutic products using CRISPR-Cas9 technology for gene editing and repair, announced today that it has closed a Series A investment
Read More